#CMGsays: Join here tomorrow for the launch of a new accredited tweetorial on optimal management of diabetic and other high-risk patients with stable CAD, particularly those with previous PCI, to reduce the risk of MI or stroke. Expert faculty is the incomparable @CMichaelGibson
And you’ll learn how these data should impact your practice: Image
1) Welcome to a tweetorial on #DAPT as it applies to optimal management of high-risk patients with stable CAD--#ACS or #stroke waiting to happen. Accredited for 0.5h by @academiccme: #physicians, #nurses, #pharmacists! I am @CMichaelGibson . . . Image
. . . and this accredited educational activity is intended for healthcare providers and is supported by grants from AstraZeneca, Bayer, Chiesi, and NovoNordisk.
2) Last month you followed an excellent Journal Club tweetorial by @gabrielsteg on #THEMIS and THEMIS-PCI. (If you didn't, go to cardiometabolic-ce.com/plts6 and check it out, and you can still get your CE/#CME credit!) You may recall that . . .
3) . . . Ticagrelor plus aspirin yielded generally consistent and favorable net clinical benefit across the diabetes-related factors in THEMIS-PCI but not in the overall THEMIS population.
4) In this #tweetorial, we will look more closely at those "diabetes-related factors" and how they helped identify patients at risk for adverse ischemic outcomes, as they may also apply to other high-risk CAD patients who do NOT have #diabetes. Here's that graphic we promised: Image
5) Pts with both #T2D and #CAD are at high risk for #CV events. If they have had ACS in the past, standard therapy for secondary prevention, independent of presence of #diabetes, includes #DAPT.
6) Prior to #THEMIS, it was unclear whether high-risk pts who had NOT had an event might actually receive safe and effective PRIMARY prevention with #DAPT. It turns out that #THEMIS and the pre-specified THEMIS-PCI together suggested . . .
7) . . . that DAPT specifically with ticagrelor and low-dose ASA could produce #netclinicalbenefit in patients with (1) T2D, (2) stable #CAD, (3) past #PCI, but no history of MI or stroke. And in fact, the #FDA then added to the indications for ticagrelor . . .
8) . . . the reduction in risk of a FIRST #MI or #stroke even if they DID NOT have T2D. Health Canada and #EMA expanded the ticagrelor label more in line with THEMIS-PCI, but the excitement is that for the first time we have #DAPT approved as primary prevention in ANY setting.
9) So let's see where you are starting here. Which of the following factors has NOT been shown to influence the incidence of major cardiovascular events in response to antihyperglycemic therapy?
11) Welcome back to this #tweetorial on #DAPT as potential PRIMARY prevention in selected high-risk cohorts! I am @CMichaelGibson and I am happy you found the ONLY source for serialized accredited tweetorials in #cardiometabolic care! @HeartBobH @GruentzigG @Drroxmehran
12) The answer to yesterday's poll is "extent of glucose control" (doi.org/10.1016/j.jacc…). While meta-analyses of major trials investigating the potential benefit of glucose control on CV outcomes have revealed that although intensive glucose control had no . . .
13) . . . overall benefit on major CV events, there was a modest reduction in MI (doi.org/10.1007/s00125… and doi.org/10.1016/S0140-…), so it is still a good idea.
14) In THEMIS, MACE incidence did increase with duration of diabetes duration HbA1c, but major bleeding event rate (overall: 1.6%) did not vary by either and was increased similarly by ticagrelor across all subgroups in both THEMIS and THEMIS-PCI.
15) The efficacy and safety of ticagrelor #DAPT did not, however, differ by baseline antihyperglycemic therapy. including #SGLT2i use, which we know likely brings its own independent CV benefits.
16) In THEMIS-PCI, but not THEMIS, ticagrelor generally produced favorable net clinical benefit across subgroups by diabetes duration, HbA1c, and antihyperglycemic medications.
17) So what do we do with this? Let's start with a graphic that @gabrielsteg used in his #tweetorial, showing the characteristics that identify CAD patients at higher risk of thrombosis/ischemia and at higher risk of bleeding from therapy: Image
18) You see there that there are multiple risk factors for #thrombosis that arise from prior #PCI: complexity, # stents, #lesions, L main stenting, etc. These characteristics indubitably arise from severity of #CAD . . .
19) . . . and that's consistent with a more aggressive #DAPT strategy as seen in THEMIS-PCI. #Diabetes, polyvascular disease, #CKD, and #heartfailure also increase ischemic risk. So when your patient has markers like these, look in parallel at major factors for bleeding risk.
20) Alas, CKD is on this list too! At least DM isn't. For obvious reason, any bleeding proclivity (whether past bad bleed, liver insufficiency, etc) is worrisome, as is baseline #anemia, which suggests there may be chronic ongoing subclinical blood loss that #DAPT might worsen.
21) Fortunately, there are many #CAD patients out there who have had PCI, who have diabetes, or who have other high-risk concerns (such as #HF). THEMIS-PCI and the resulting label expansion for ticagrelor suggest that these patients,
22) if without those major bleed concerns, would benefit from extended #DAPT. So let's consider a case: 70M, with known CAD and elective PCI last year (and completed 12 months DAPT), as T2D on an #SGLT2i, is in your office. He had no bleeding while on ticagrelor DAPT. Would you:

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with cardio-met

cardio-met Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @cardiomet_CE

21 Jun
Join here tomorrow for the launch of a new accredited tweetorial on DAPT in patients with stable CAD+diabetes who have not (yet!) had an MI or stroke! Earn 0.5 CE/CME credits: physicians, nurses, pharmacists! Expert faculty @gabrielsteg. #medtwitter @academiccme #CardioTwitter
1) Welcome to a #tweetorial on #DAPT in patients with stable CAD+#diabetes who have not had an MI or stroke. Accredited for 0.5h by @academiccme: #physicians, #nurses, #pharmacists! I am @gabrielsteg . . .
. . . This educational activity is intended for healthcare providers and is supported by grants from Abbott, AstraZeneca, Bayer, Chiesi, and NovoNordisk.
Read 30 tweets
24 May
Join here tomorrow for the launch of a new accredited tweetorial on the expanding role of #SGLT2i in CV disease! Earn 0.5 CE/CME credits: physicians, nurses, pharmacists! Expert faculty @mvaduganathan. #medtwitter @academiccme #diabetesmanagement @endocrinenetwrk
1) Welcome to a Tweetorial on #SGLT2i & CV health. “Flozinators of the world, unite!” Accredited for 0.50h by @academiccme: #physicians, #nurses, #pharmacists. I am @mvaduganathan . . . Image
. . . and this educational activity, which is intended for healthcare providers, is supported by grants from Abbott, AstraZeneca, Bayer, Chiesi, and NovoNordisk.
Read 25 tweets
19 Apr
Watch here tomorrow for the launch of a new accredited tweetorial on use of P2Y12 inhibitor monotherapy after PCI! Earn 0.5 CE/CME credits: physicians, nurses, pharmacists! Expert faculty @SVRaoMD. #medtwitter @academiccme #cardiotwitter
1) Welcome to a tweetorial on the use of P2Y12 inhibitor monotherapy after PCI! Accredited for 0.50 credits by @academiccme: physicians, nurses, pharmacists! I am @SVRaoMD. Image
2) This series is supported by educational grant funding from Abbott, AstraZeneca, Bayer, Chiesi, and NovoNordisk. Follow this thread for credit. And here is a case …
Read 25 tweets
25 Mar
Watch here tomorrow for the launch of a new accredited tweetorial on #hypertension management in #AorticDissection! Earn 0.5 CE/CME credits: physicians, nurses, pharmacists! Expert faculty @JerroldLevy. #medtwitter @academiccme @MedTweetorials @ACEPNow @ENAorg @CCPharmacists
1) Welcome to a tweetorial on #hypertension management in #AorticDissection! Accredited for 0.50 CE/CME credits by @academiccme: physicians, nurses, pharmacists! Expert faculty @JerroldLevy. Hello @DocAnitaGupta, @LorraineC_MD, @WarnerMatthewA, @DrManiCTSurgery, @PatrickGoldste4 Image
2) . . . Supported by educational grant funding from Abbott, AstraZeneca, Bayer, Chiesi, NovoNordisk. Follow this thread for credit. And here is a case . . .
Read 27 tweets
22 Dec 20
6/
High-degree AV block was the most powerful predictor of cardiac death. Guidelines currently don’t recommend routine ICM post-MI, unless patients have recurrent unexplained syncope with systolic impairment and don’t have a current indication for an ICD.
7/
REVISE study: 103 pts with epilepsy but likely misdiagnosed. Enrolled if 3/+transient LOC episodes in yr before enrol. ICM recorded profound bradyarrhythmia or asystole with convulsive features in 21%, who were offered pacemaker. After pacing and d/c sz meds, 60% became asx.
8/
ESUS cryptogenic stroke: a good indication for ICM, as recurrence is common and AF detection might allow treatment. Intermittent monitoring (annual 24h or quarterly 7d Holter) for AF inferior to cont ICM. ICMs shown to be a cost-effective dx'ic tool for sec prevention in ESUS.
Read 7 tweets
19 Dec 20
Welcome to our first accredited Twitter Journal Club! Each earns 0.5h credit for docs, nurses, pharmacists. Starting tomorrow, learn about insertable cardiac monitors. @academiccme #cardiotwitter #medtwitter
Article assignment at researchgate.net/profile/Rafi_S…
1/
Welcome to Journal Club! This program is accredited for 0.5h CE credit. Complete it and then follow directions (in next Thursday’s final tweet in this series) for claiming credit. So easy! This program supported by grants from Abbott and Bayer. Ready to go???
2/
Prolonged rhythm monitoring with a SQ insertable cardiac monitor (ICM) is of diagnostic value in patients with unexplained recurrent syncope. DDx includes unproven epilepsy, unexplained falls, and other arrhythmias.
Read 7 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!

Follow Us on Twitter!

:(